CRI Genetics AI Visibility Market Strategy Report - DNA Testing Kits

Answer Capsule

CRI Genetics holds almost no recommendation-stage visibility in the DNA testing kits category. The October 2026 LLM Authority Index benchmark shows the brand mentioned in 2.31% of qualified AI responses and recommended in only 0.53%, with a single top-three placement and no rank-one placements across 563 qualified observations. The clearest weakness is the gap between presence and recommendation: CRI Genetics is referenced but almost never chosen. The clearest opportunity is to convert that small base of mentions into valid recommendations inside the brand recommendation cluster, where every qualified observation in the benchmark currently sits.

Who This Report Is For

This report is written for CRI Genetics marketing, brand, and growth leadership, and for category analysts tracking how AI search and chat surfaces present DNA testing brands at the moment buyers form a shortlist.

Report Card

Executive Summary

CRI Genetics is visible but under-recommended in AI-generated DNA testing recommendations. The October 2026 benchmark records 13 mentions across 563 qualified observations, a raw mention presence rate of 2.31%, and only 3 valid recommendations, a valid recommendation coverage rate of 0.53%. The brand is referenced in a small number of answers but is almost never surfaced as a recommended option.

The recommendation picture is thinner still. CRI Genetics recorded 1 top-three placement (0.18% top-three rate) and 0 rank-one placements in October 2026. Its average recommended rank of 4.67 applies to a very small number of rank-eligible recommendations, so it should be read as directional rather than precise.

Framing is the one relatively stable signal. Of the 13 mentions, 3 were positive, 10 were neutral, and 0 were negative, producing a net sentiment score of 0.2308. That is the lowest net sentiment score among the four brands with meaningful presence in the category, and it reflects a profile dominated by neutral, reference-style mentions rather than active endorsement.

The strongest cluster is the only cluster with qualified data. All 563 qualified observations fall into the brand recommendation cluster, covering discovery and consideration intent. The benchmark captured no qualified observations in the pricing and value or multi-brand comparison clusters, so CRI Genetics has no measurable public signal on price positioning or head-to-head comparison.

The strongest platform signal is Google AI Overviews, where CRI Genetics recorded 3 mentions, 2 valid recommendations, and a 1.36% valid recommendation coverage rate. That is the highest platform-level coverage the brand achieved in October 2026, and it is still a very small base.

The clearest gap is competitive displacement. AncestryDNA holds a 73.00% top-three rate and a 69.63% rank-one rate in the same observation set, while 23andMe holds 61.63% and 1.60% and MyHeritage DNA holds 49.73% and 0.89%. CRI Genetics is present in the same answers but is not part of the recommendation set those answers produce.

What CRI Genetics Is Winning

Questions This Section Answers

• Where does CRI Genetics have measurable AI visibility on a specific platform?
• What does CRI Genetics' sentiment profile look like compared to competitors?

The evidence-backed wins for CRI Genetics are narrow, and the report should say so plainly.

The brand has no negative framing. Across 13 mentions in October 2026, CRI Genetics recorded 0 negative mentions and 0 negative visibility rate. In a category where 23andMe recorded 10 negative mentions and Nebula Genomics recorded 2, the absence of negative framing is a real, if modest, asset.

The brand has a measurable presence on Google AI Overviews. CRI Genetics recorded 3 mentions and 2 valid recommendations on that surface, giving it a 1.36% valid recommendation coverage rate, the highest of any platform tracked in October 2026. It also recorded 1 top-three placement on Google AI Overviews, the only top-three placement the brand earned in the month.

The brand retains a small rank-eligible footprint. CRI Genetics recorded 3 rank-eligible recommendations with an average recommended rank of 4.67, which indicates that when the brand does enter a recommendation set, it is not placed last.

Beyond these three points, the October 2026 data does not support a stronger claim. CRI Genetics holds no rank-one placements, no presence on ChatGPT, Copilot, or Perplexity, and a valid recommendation coverage rate below 1%.

Where CRI Genetics Has the Clearest AI Visibility Gaps

Questions This Section Answers

• How large is the gap between CRI Genetics' presence and its valid recommendation coverage?
• Which tracked AI platforms show no CRI Genetics presence at all?
• How far behind is CRI Genetics on top-three and rank-one placements versus category leaders?

The defining gap for CRI Genetics is recommendation conversion, not presence. The brand appears in 2.31% of qualified observations but converts only 0.53% of them into valid recommendations. That means roughly four out of every five times CRI Genetics is mentioned, it is not recommended.

The gap widens when compared to the category leaders. AncestryDNA converts 99.64% presence into 73.18% valid recommendation coverage. 23andMe converts 97.16% presence into 67.32% coverage. MyHeritage DNA converts 79.75% presence into 59.50% coverage. CRI Genetics converts 2.31% presence into 0.53% coverage. The brand is not losing a recommendation race at the margin; it is largely absent from the recommendation set that AI systems build.

Platform coverage is also uneven. CRI Genetics recorded no mentions on ChatGPT, no mentions on Copilot, and no mentions on Perplexity in October 2026. Its entire footprint sits on Google AI Overviews (3 mentions), Google AI Mode (8 mentions), and Gemini (2 mentions). Three of the six tracked platforms produced no CRI Genetics presence at all.

The top-three gap is the sharpest single number. CRI Genetics recorded 1 top-three placement against 563 qualified observations, a 0.18% top-three rate. AncestryDNA recorded 411 top-three placements, 23andMe recorded 347, MyHeritage DNA recorded 280, and FamilyTreeDNA recorded 143. Even Living DNA, at 17.23% valid recommendation coverage, recorded 15 top-three placements. CRI Genetics is competing for a slot it is not currently reaching.

The rank-one gap is absolute. CRI Genetics recorded 0 rank-one placements in October 2026. AncestryDNA recorded 392, 23andMe recorded 9, Nebula Genomics recorded 7, MyHeritage DNA recorded 5, and African Ancestry recorded 1. The brand is not being surfaced as a first recommendation on any tracked platform.

Biggest Opportunity

Questions This Section Answers

• How can CRI Genetics convert its neutral mentions into valid recommendations?
• Which AI surfaces offer the highest-leverage path from reference to recommendation?

The single biggest opportunity for CRI Genetics is to convert its existing neutral mentions into valid recommendations inside the brand recommendation cluster, the only cluster with qualified data in October 2026.

The mechanics of that opportunity are specific. CRI Genetics already appears in a small number of AI answers, and 10 of its 13 mentions are neutral rather than negative. Neutral mentions indicate the brand is being referenced as context, a comparison anchor, or a listed option rather than as a recommended choice. The path from reference to recommendation runs through the prompt, page, and citation layers that AI systems draw on when they build a shortlist.

The highest-leverage surface is Google AI Overviews, where CRI Genetics already holds its strongest coverage at 1.36% and its only top-three placement. Google AI Mode is the second surface to prioritize, since it produced 8 of the brand's 13 mentions. Both surfaces are search-adjacent, which means the public evidence layer that supports them is more directly addressable than the conversational surfaces where the brand currently has no presence.

Competitive Landscape

Questions This Section Answers

• Which DNA testing brands hold the strongest recommendation power, and where does CRI Genetics sit among them?
• How does CRI Genetics' top-three and rank-one performance compare to AncestryDNA, 23andMe, and MyHeritage DNA?

AncestryDNA holds dominant recommendation power in the DNA testing kits category, with 23andMe as the strongest challenger and MyHeritage DNA as the clearest placement riser. CRI Genetics sits near the bottom of the tracked set, with presence but almost no recommendation conversion.

Average recommended rank covers rank-eligible recommendations only.

CRI Genetics ranks eighth of ten on top-three rate and holds no rank-one placements. Its average recommended rank of 4.67 is the lowest in the tracked set, but it rests on only 3 rank-eligible recommendations, so it should be read as directional. The brand's net sentiment score of 0.2308 is the second lowest in the category, ahead of only Health Nucleus, which recorded no mentions at all.

Prompt Evidence

Questions This Section Answers

• What happens when buyers ask high-intent questions like 'What is the best DNA ancestry kit to buy?'
• Which prompts show CRI Genetics being mentioned without receiving recommendation credit?

Google AI Overviews / Brand Recommendation Prompt: "What is the best DNA ancestry kit to buy?" Result: CRI Genetics appeared in the response but was not placed in the top three recommended options.

Google AI Mode / Brand Recommendation Prompt: "What is the most accurate DNA test to take?" Result: CRI Genetics was mentioned as a reference point, with no valid recommendation credit recorded.

Gemini / Brand Recommendation Prompt: "How do you find out what races you are mixed with?" Result: CRI Genetics was mentioned neutrally, contributing to the brand's neutral mention count rather than its recommendation count.

Google AI Overviews / Brand Recommendation Prompt: "What DNA test is more accurate?" Result: CRI Genetics received one of its two Google AI Overviews valid recommendations, the brand's strongest single platform outcome in October 2026.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map every prompt where CRI Genetics is mentioned but not recommended, and identify which competitor takes the recommendation slot in each case.

Phase 2: Recommendation Readiness Plan Prioritize the brand recommendation cluster and the Google AI Overviews and Google AI Mode surfaces where CRI Genetics already has measurable presence.

Phase 3: Owned Answer Layer Buildout Build owned pages that answer the specific high-intent prompts where CRI Genetics currently appears as a neutral reference, so AI systems have a clear recommendation-shaped source to draw on.

Phase 4: Citation / Authority Layer Development Strengthen the review, guide, and comparison sources that AI systems cite in this category, since the top cited domains in October 2026 were dominated by review and guide properties rather than brand-owned pages.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track top-three rate, rank-one rate, and valid recommendation coverage month over month to confirm whether neutral mentions are converting into recommendation credit.

Why This Matters

AI presence alone is not enough. CRI Genetics is mentioned in AI answers, but it is almost never recommended, and the recommendation set is what shapes the buyer shortlist. A brand that appears as a neutral reference while competitors appear as recommended options is losing the decision moment even when it is technically visible.

The next move is targeted correction of the prompt, page, and citation layers. That means identifying the specific questions where CRI Genetics is mentioned but not chosen, building owned and third-party sources that answer those questions in recommendation form, and tracking whether the brand's top-three and rank-one rates move as a result.

Core Metrics

Sentiment Score

Questions This Section Answers

• How is CRI Genetics' sentiment score calculated, and what does it reveal about mention quality?
• Why are neutral references a weaker signal than positive mentions in interpreting AI visibility?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For CRI Genetics in October 2026: (3 × 1 + 10 × 0 + 0 × -1) / 13 = 0.2308.

This matters because unclassified mention counts are misleading. A brand with 13 mentions sounds more visible than it is if those mentions are neutral references rather than recommendations. Share of voice is a diagnostic metric, not a business KPI.

A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. CRI Genetics' 13 mentions break down as 3 positive and 10 neutral, with no negative framing. That profile indicates the brand is being referenced as context rather than endorsed as a choice. Counting all mentions as wins would overstate the brand's position considerably.

Classified sentiment is required before interpreting AI visibility. The 0.2308 score tells a more accurate story than the raw mention count: CRI Genetics is present in the conversation, but the conversation is not recommending it.

Sentiment by Platform

Questions This Section Answers

• On which platforms does CRI Genetics receive positive versus neutral mentions?
• What does the platform-level sentiment breakdown say about where the brand is recommendation-led versus merely present?

Methodology

1. This report is a benchmark-based analysis of CRI Genetics' AI recommendation visibility in the DNA testing kits category for October 2026. It is not a client implementation result.
2. The reporting window is October 2026, with the July 2026 baseline used for comparison where the source benchmark provides it.
3. Six AI and search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The October 2026 measurement began with 800 prompt-surface observations and produced 563 qualified observations after qualification. Seven observations were classified as irrelevant.
5. The competitor universe contains ten tracked brands: AncestryDNA, 23andMe, MyHeritage DNA, FamilyTreeDNA, Living DNA, Nebula Genomics, African Ancestry, CRI Genetics, tellmeGen, and Health Nucleus.
6. One public high-intent cluster carried qualified data in October 2026: Brand Recommendation, covering discovery and consideration intent. The benchmark defines two additional clusters, Pricing and Value and Multi-Brand Comparison, but neither produced qualified observations in the current series.
7. Stage 0 extraction retains the query, AI or search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources.
8. A mention is any qualified observation in which CRI Genetics appears in the AI response in any form, including neutral references and comparison anchors.
9. A valid recommendation is a qualified observation in which CRI Genetics receives explicit recommendation credit. Neutral, cautionary, and listed-only mentions are not counted as valid recommendations.
10. Top-three rate and rank-one rate are calculated within the qualified observation set of 563, not the 800 raw prompts collected.
11. Average recommended rank covers rank-eligible recommendations only. CRI Genetics recorded 3 rank-eligible recommendations in October 2026, so its average recommended rank of 4.67 should be read as directional rather than precise.
12. The benchmark records change; it does not by itself establish why a change occurred. Source presence is evidence about the information environment, not proof that a source caused a recommendation.

See How AI Is Recommending Your Brand

The public benchmark shows where CRI Genetics stands in AI-generated DNA testing recommendations. A company-level AI visibility audit shows which prompts the brand wins, which competitor takes the recommendation when CRI Genetics is mentioned but not chosen, and which sources shape those answers across ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.